Patent intelligence · US
US 10251851
Bicyclic analgesic compounds
Bicyclic analgesic compounds
Patent details — US 10251851
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 9, 2019
- Expiration
- Apr 4, 2039
- Applicant
- Zeno Royalties & Milestones, LLC
- Claims
- 24
- CPC classes
- A61K, A61K31/13, A61K31/133, A61K31/14
Quick answer
US 10251851 (Bicyclic analgesic compounds) is held by Zeno Royalties & Milestones, LLC. Status: granted. Granted Apr 9, 2019. Expires Apr 4, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Zeno Royalties & Milestones, LLC
- Grant date
- Expiration
- Claims
- 24
- CPC classes
- A61K, A61K31/13, A61K31/133, A61K31/14, A61K31/16, A61K31/215
More from Zeno Royalties & Milestones, LLC
Related pharmaceutical patents in our USPTO index.
-
US 12257224
Methods of administration for highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker
granted -
US 10632255
Drug infusion device
granted -
US 10308609
Bicyclic compounds
granted -
US 10117848
Highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker and uses thereof
granted -
US 10010524
Short acting phenylalkylamine calcium channel blockers and uses thereof
granted -
US 10010523
Short acting phenylalkylamine calcium channel blockers and uses thereof
granted -
US 10010522
Short acting phenylalkylamine calcium channel blockers and uses thereof
granted
Frequently asked questions
What is US patent 10251851?
US 10251851 (Bicyclic analgesic compounds) is held by Zeno Royalties & Milestones, LLC. Status: granted. Granted Apr 9, 2019. Expires Apr 4, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10251851?
Zeno Royalties & Milestones, LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 12 pharmaceutical patents for this assignee.
When does US 10251851 expire?
Our index shows an expiration date of Apr 4, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.